PRAC recommends withdrawal of marketing authorisations for levamisole medicinesLeukoencephalopathy confirmed as a serious side effect of levamisoleEMA’s safety committee, the…, Agenda Agenda of the PRAC meeting 9-12 February 2026Draft Reference…, PRAC statistics: February 2026 , PRAC statistics: February 2026 English (EN) (172.98 KB - PDF)First…, Concluded referrals Levamisole-containing medicinal products, Glossary Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association…